POLB 001 CRS patent granted in Canada
Poolbeg Pharma PLC has been granted a patent in Canada for its POLB 001 cancer immunotherapy-induced Cytokine Release Syndrome (CRS) treatment, strengthening its global intellectual property portfolio. This patent, which covers the use of any p38 MAPK inhibitor, including POLB 001, for preventing CRS, follows a similar grant in Australia and was expedited through the Patent Prosecution Highway. The company's IP now extends to both cancer immunotherapy-induced CRS and severe influenza across multiple jurisdictions, enhancing POLB 001's future value and appeal to potential partners, with interim data from the TOPICAL trial anticipated this summer.
Select text to share a quote on X · sign in to keep highlights & notes in your POLB notes
11 May 2026 - Poolbeg Pharma (AIM: POLB, 'Poolbeg' or the 'Company'), a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field, announces that it has received formal notification of the grant for its POLB 001 cancer immunotherapy-induced Cytokine Release Syndrome ("CRS") patent application from the Canadian patent office.
This represents the second national grant within Poolbeg's cancer immunotherapy-induced CRS patent family, following the grant by IP Australia announced in March 2026, and marks a further important milestone for the Company. This patent covers the use of any p38 MAPK inhibitor, including POLB 001, for the prevention of cancer immunotherapy-induced CRS, and is underpinned by proprietary data generated by Poolbeg.
Poolbeg filed its initial oncology patent applications in the UK in January 2023 before entering the international Patent Cooperation Treaty system in January 2024. This new patent grant was accelerated through the Patent Prosecution Highway, which enables expedited examination in participating countries where a favourable ruling has already been secured in another participating jurisdiction.
The Company's IP portfolio now spans both cancer immunotherapy-induced CRS and severe influenza across multiple jurisdictions, and Poolbeg continues to pursue protection in further territories. This grant further strengthens the Company's robust intellectual property portfolio, enhancing POLB 001's future value and appeal to potential partners.
Jeremy Skillington, PhD, Chief Executive Officer of Poolbeg Pharma, said: "This Canadian patent grant, coming shortly after our first oncology patent grant in Australia, further strengthens our IP position for POLB 001 and demonstrates the momentum we have built in expanding this patent family globally. With interim data from the TOPICAL trial expected this summer, we believe this patent grant further enhances the attractiveness of POLB 001 to prospective partners. We will continue to pursue coverage in other jurisdictions and look forward to updating shareholders on our progress."
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.